MetaCap

Sol-Gel Technologies (SLGL) vs Whitehawk Therapeutics (WHWK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sol-Gel Technologies (SLGL) has outperformed Whitehawk Therapeutics (WHWK) over the past year, gaining 50.5% versus a gain of 45.5%. Over five years, SLGL leads with a -28.4% price change compared with -86.4% for WHWK. Whitehawk Therapeutics is the larger company by market cap ($181.2 million vs $180.6 million), about 1.0 times the size, while Sol-Gel Technologies is growing revenue faster (+68.0% vs -72.5%).

Sol-Gel Technologies converts more of its revenue into profit, with a net margin of -31.6% versus -288.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SLGL+50.53%WHWK+45.50%
+176%+84%-8%
Nov 21, 20251 yearNov 20, 2026
SLGL-35.62%WHWK-87.61%
+12%-44%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SLGL versus WHWK key metrics
MetricSLGLWHWK
Share price$55.17$3.07
Market cap$180.63M$181.16M
1-day change+2.02%-1.60%
YTD return+30.92%+26.86%
1-year return+50.53%+45.50%
5-year return-28.44%-86.36%
EPS (TTM)$-5.22$-1.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$19.39M$7.14M
Revenue growth (YoY)+68.04%-72.50%
Net income (latest FY)$-6.13M$-20.60M
Gross margin—89.36%
Operating margin-38.88%-1601.12%
Net margin-31.60%-288.26%
52-week high$97.97$5.50
52-week low$34.47$2.10
Distance from 52-week high-43.69%-44.13%
Analyst consensusstrong_buybuy
Avg. price target upside+181.86%+151.14%
Average volume47.38K348.68K
Shares outstanding3.27M59.01M
Employees2837
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Sol-Gel Technologies is more profitable, keeping -31.6 cents of every revenue dollar as net income versus -288.3 cents for Whitehawk Therapeutics.
  • Sol-Gel Technologies grew revenue faster in its latest fiscal year (+68.04% vs -72.50%).

About Sol-Gel Technologies

SLGL stock →

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Whitehawk Therapeutics

WHWK stock →

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees

SLGL vs WHWK FAQ

Which is bigger, Sol-Gel Technologies or Whitehawk Therapeutics?

Whitehawk Therapeutics (WHWK) is larger, with a market capitalization of $181.16M compared with $180.63M for Sol-Gel Technologies (SLGL).

Which stock has performed better over the past year, SLGL or WHWK?

SLGL returned +50.53% over the past 12 months, compared with +45.50% for WHWK (price return, excluding dividends). Past performance does not predict future results.

Are Sol-Gel Technologies and Whitehawk Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons